Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854041 | PMC |
| http://dx.doi.org/10.1093/rheumatology/kev365 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rosai-Dorfman disease mimicking IgG4-related disease.
Wien Med Wochenschr
September 2025
Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34093, Istanbul, Turkey.
Rosai-Dorfman disease (RDD) is a rare histiocytic disorder that may clinically and histologically resemble IgG4-related disease (IgG4-RD), especially in the presence of IgG4-positive plasma cell infiltration. In this case, a 69-year-old woman with generalized lymphadenopathy, constitutional symptoms, and elevated IgG4 levels was initially suspected to have IgG4-RD based on core needle biopsy. However, further evaluation with excisional lymph node biopsy revealed emperipolesis and S100-positive histiocytes, confirming the diagnosis of RDD.
View Article and Find Full Text PDFWiskott-Aldrich syndrome complicated with IgG4-related Sclerosing disease: A case report and literature review.
Allergol Immunopathol (Madr)
September 2025
Division of Immunology and Allergy, Department of Internal Medicine, Ankara University School of Medicine, Ankara, Türkiye.
Wiskott-Aldrich Syndrome (WAS) is an X-linked immunodeficiency characterized by eczema, microthrombocytopenia, and recurrent infections. Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory disorder involving various organs. We present a 34-year-old male with WAS who developed cervical lymphadenopathy and parotid gland swelling.
View Article and Find Full Text PDFIgG4-Related Disease Inflamatory Pseudotumor Affecting the Sternoclavicular Joint: A Clinical Challenge.
Case Reports Immunol
August 2025
General Hospital Dr. César Cals, Avenida do Imperador, 545, Centro, Fortaleza, Ceará, Brazil.
IgG4-related disease (IgG4-RD) is a rare, progressive, and immune-mediated fibroinflammatory disorder that primarily affects middle-aged men and is more prevalent in Asian populations. Although extensively studied, its pathophysiology remains incompletely understood. This case report describes a 44-year-old male presenting with multiple abscesses and progressive inflammatory symptoms, ultimately diagnosed with IgG4-RD with musculoskeletal involvement.
View Article and Find Full Text PDFStructural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development.
Curr Neuropharmacol
August 2025
Department of Neurology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
Introduction: Amyloid-beta-targeting monoclonal antibodies (mAbs) for Alzheimer's disease frequently induce amyloid-related imaging abnormalities with hemorrhage (ARIA-H), yet systematic comparisons of ARIA-H incidence across therapeutic agents remain limited. Post-approval research prioritizes dosing over mechanism, leaving unresolved whether ARIA-H variations originate from intrinsic mAb properties. We address two gaps: comparative ARIA-H risk stratification among clinically available/investigational mAbs, and elucidation of structural/functional features influencing ARIA-H susceptibility.
View Article and Find Full Text PDFDiscontinuation Reasons and Drug Survival of Dupilumab in Real-World Adult Atopic Dermatitis Patients in Three Healthcare Facilities in Tokyo and Yokohama (2018-2023).
J Dermatol
September 2025
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Dupilumab, a fully human IgG4 monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling by blocking the shared IL-4α subunit, is the first targeted systemic therapy for moderate-to-severe atopic dermatitis (AD). The drug was introduced in Japan in April 2018, along with other countries around the same time, leading to a dramatic improvement in patients' quality of life. This study aims to provide practical insights into the real-world use of dupilumab to support decision-making in drug selection and patient education.
View Article and Find Full Text PDF